Oncopeptides AB (ONCO.ST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in SEK.

Revenue Annual

0 15M 30M 45M 2023: 35.2M 2024: 31.6M 2023 2024

Gross Profit Annual

0 15M 30M 45M 2023: 36.3M 2024: 29M 2023 2024

Operating Income Annual

-300M -200M -100M 0 100M 200M 300M 2023: -253.4M 2024: -283.5M 2023 2024

Net Income Annual

-300M -200M -100M 0 100M 200M 300M 2023: -249.1M 2024: -284.6M 2023 2024

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M 2023: -279.5M 2024: -260.6M 2023 2024

Free Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M 2023: -279.6M 2024: -260.9M 2023 2024

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.